Adverse events associated with monoclonal antibodies used for treatment of COVID-19: A systematic review and meta-analysis.

ABSTRACT:

Aims

This review aimed to synthesise the evidence related to the incidence of serious and non-serious adverse events with the use of monoclonal antibodies (mAbs) among COVID-19 patients.

Methods

Databases were searched from January 2020 to September 2023 for randomized clinical trials (RCTs) that used mAbs for the treatment of COVID-19 regardless of disease severity. Study screening, data extraction and data analysis were performed independently by two reviewers. The Cochrane risk of bias 1.0 tool was used for methodological quality assessment.

Results

Sixteen studies were identified for analysis with 9682 participants in the intervention arm and 10 115 participants in the control arm. Seven trials reported hepatoxicity and there was a statistically significant increa

SUBMITTER: Htet H 

PROVIDER: S-EPMC12035595 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature